Navigation Links
Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Date:8/5/2008

- 88% of patients achieve undetectable HCV RNA levels following 4 weeks of

treatment with R7128 1000mg BID with Pegasys(R) plus Copegus(R) - - Safety and tolerability comparable to placebo administered with Pegasys

plus Copegus -

PRINCETON, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces the preliminary results of the third cohort of a 4-week Phase 1 clinical trial evaluating R7128 1000mg twice daily (BID) in combination with the standard of care (SOC), Pegasys(R) (pegylated interferon) plus Copegus(R) (ribavirin), in 31 treatment-naive patients chronically infected with hepatitis C virus (HCV) genotype 1. R7128, a prodrug of PSI-6130, is a nucleoside analogue polymerase inhibitor of HCV that is being developed in collaboration with Roche.

As previously reported for Cohorts 1 and 2 of this study, R7128 has demonstrated potent short-term antiviral activity and was generally safe and well tolerated at doses of 500mg and 1500mg administered for 28 days in combination with SOC. In Cohort 3, a new formulation of R7128 1000mg BID was administered in combination with SOC. Of the 31 patients enrolled, 25 patients received R7128 1000mg BID and 6 received placebo. 88% (22 of 25) patients receiving R7128 1000mg BID with SOC for 4 weeks achieved undetectable HCV RNA levels (<15 IU/mL). This high rate of Rapid Virologic Response (RVR) compares favorably with the 85% RVR demonstrated earlier this year with R7128 1500mg BID in combination with SOC. Based on these results, R7128 1000mg BID will be among the doses carried forward into Phase 2b studies, which we expect to be submitted to the FDA this Fall.

The preliminary safety and tolerability of R7128 1000mg BID
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 This BCC Research report discusses ... major players, market growth and size, and opportunities for different ... revenue through 2018. Patent analysis in the report focuses on ... U.S., Europe and Japan ... Define and discuss the global medical device technologies market. - ...
(Date:9/18/2014)... 2014   Fruit Street Health (Fruit Street), ... round of funding. The round, which ... series of individual investors, the majority of whom are ... initial round are; Houston Cardiology Consultants Partner Asif ... Childs, Rapha Family Medicine Practice Owner Frances Ilozue ...
(Date:9/18/2014)... 18, 2014  ADM Tronics Unlimited, Inc. (OTCQB: ... to its corporate Advisory Board for business development. ... the Harvard Medical School and Visiting Professor at ... his Masters degree in Electronics Engineering and his ... of Bologna. After spending a year as a ...
Breaking Medicine Technology:Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3
(Date:9/18/2014)... Companies in the Carbon Dioxide Production ... to downstream industries in either gas, liquid or solid ... and beverage manufacturers. Food producers use carbon dioxide to ... The gas is also used as a packaging preservative ... soft drinks, beer and other beverages. According to IBISWorld ...
(Date:9/18/2014)... Alan Mozes HealthDay Reporter , ... to emergency room waiting times, patients seeking care at larger ... the clock than those seen at smaller or more rural ... our ability to provide timely emergency care varies dramatically across ... of the new research, Dr. Renee Hsia, an associate professor ...
(Date:9/18/2014)... Daily supplements of selenium or vitamin E don,t seem ... among men, a new study indicates. Previous animal ... prevent cataracts. To investigate this further, William Christen, from ... Boston, and his colleagues examined data from a randomized, ... was initially designed to study prevention of prostate cancer. ...
(Date:9/18/2014)... together with the Chinese Thoracic Society (CTS) announced ... CHEST World Congress 2016 will be held in ... sleep medicine from around the world are expected ... 2016. , CHEST World Congress 2016 will ... keynote addresses, presentations by leading health-care experts, and ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 TayganPoint ... announced today that President and co-founder John Cassimatis ... Innovation Award Winners for 2014, recognizing the region’s ... as an emerging executive of the year. , ... and life sciences that continue to shape the ...
Breaking Medicine News(10 mins):Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 3Health News:ER Waiting Times Vary Significantly, Studies Find 2Health News:ER Waiting Times Vary Significantly, Studies Find 3Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:CHEST announces China as site of CHEST World Congress 2016 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2
... Rehab MarketDETROIT, March 10 David Glancy, a complex ... has joined Alliance Seating & Mobility (ASM), ... companies. Glancy is an Assistive Technology Professional ... and provides power mobility solutions for pediatrics and adults ...
... WASHINGTON, March 10 To guide healthcare systems in ... the National Quality Forum (NQF) is releasing its 2009 ... pace of adoption of Safe Practices nationwide, a year-long ... Practices implementation strategies and commentary from experts in the ...
... soar past $2.5 trillion and more than 47 million people ... medical options to ensure health care reform is successful, argues ... Americans die each year because of their lack of insurance, ... that save very few lives or yield only a few ...
... of fondness and relief. Fondness for the good memories, and relief ... gossip, SATs, fights with parents is behind us. ... that even stressful times from the teenage years exact a physical ... , Andrew J. Fuligni, a professor of psychiatry at the ...
... ROCHESTER, Minn., March 10 Here are highlights from ... . You may cite this publication as often as ... attribution is required. Reprinting is allowed ... your editorial policies permit: Visit www.bookstore.mayoclinic.com or ...
... CPC of America, Inc. (OTC Bulletin Board: ... therapeutic devices that enhance the quality of patient ... is actively pursuing the development of proprietary polyethylene ... global commercialization strategy for MedClose(TM). MedClose(TM) is ...
Cached Medicine News:Health News:Veteran Rehab Specialist, David Glancy, Joins Fast-Growing Alliance Seating & Mobility in Michigan 2Health News:'Patient Safety Can't Wait' - NQF Calls for Faster Spread of Safe Practices 2Health News:'Patient Safety Can't Wait' - NQF Calls for Faster Spread of Safe Practices 3Health News:'Patient Safety Can't Wait' - NQF Calls for Faster Spread of Safe Practices 4Health News:Limited resources, unlimited needs: Americans should ration health care, says MSU ethicist 2Health News:Limited resources, unlimited needs: Americans should ration health care, says MSU ethicist 3Health News:Teenage stress has implications for adult health 2Health News:March 2009 Mayo Clinic Women's HealthSource Highlights Molecular Breast Imaging, Canes and Walkers, Training for an Event and Hormone Therapy for Women 2Health News:March 2009 Mayo Clinic Women's HealthSource Highlights Molecular Breast Imaging, Canes and Walkers, Training for an Event and Hormone Therapy for Women 3Health News:March 2009 Mayo Clinic Women's HealthSource Highlights Molecular Breast Imaging, Canes and Walkers, Training for an Event and Hormone Therapy for Women 4Health News:March 2009 Mayo Clinic Women's HealthSource Highlights Molecular Breast Imaging, Canes and Walkers, Training for an Event and Hormone Therapy for Women 5Health News:March 2009 Mayo Clinic Women's HealthSource Highlights Molecular Breast Imaging, Canes and Walkers, Training for an Event and Hormone Therapy for Women 6Health News:CPC Pursues Development of Proprietary Synthetic Sealants as part of MedClose(TM) Global Commercialization 2Health News:CPC Pursues Development of Proprietary Synthetic Sealants as part of MedClose(TM) Global Commercialization 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: